Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study
| Autor: | Kang Sim, Wing Aung Myint, Tian-Mei Si, Van Cuong Tran, Yanling He, Yong Chon Park, Ajit Avasthi, Takahiro A. Kato, Fung Kum Helen Chiu, Kok Yoon Chee, Naotaka Shinfuku, Norman Sartorius, Shigenobu Kanba, Qian Hui Chew, Sandeep Grover, Samudra Kathiarachchi, Mian-Yoon Chong, Andi J. Tanra, Ross J. Baldessarini, Chay Hoon Tan, Shih Ku Lin, Dulshika Waas, Afzal Javed, Adarsh Tripathi, Shu Yu Yang, Roy Abraham Kallivayalil, Wai Kwong Lim, Min Soo Lee, Pichet Udomratn, Seon Cheol Park, Golam Rabbani, Kim Viet Nguyen, Yu-Tao Xiang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Asia Dose Sedation medicine.medical_treatment Severity of Illness Index Young Adult Antimanic Agents Internal medicine Humans Medicine Pharmacology (medical) Dosing Practice Patterns Physicians' Antipsychotic Dose-Response Relationship Drug business.industry Middle Aged medicine.disease Hospitalization Psychiatry and Mental health Mood Neurology Schizophrenia Adjunctive treatment Drug Therapy Combination Female Neurology (clinical) medicine.symptom business Body mass index Antipsychotic Agents |
| Zdroj: | Human Psychopharmacology: Clinical and Experimental. 35:1-7 |
| ISSN: | 1099-1077 0885-6222 |
| DOI: | 10.1002/hup.2752 |
| Popis: | OBJECTIVE Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). METHODS Within an Asian research consortium focusing on pharmaco-epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (>1000 mg/day lithium-equivalents) and clinical correlates. RESULTS Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p < 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non-remission of illness, behavioral disorganization, aggression, affective symptoms, and social-occupational dysfunction), and treatment-related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. CONCLUSIONS Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |